This is the second webinar in the BioMedical SIG webinar series, “From Research to Development – Paths to Cross the Valley of Death in Life Sciences”, which showcases initiatives available to European KTOs to maturate technologies with potential in TRL and CRL, without the creation of a spin-off.
In this session, speakers Peter Nussbaumer and Gernot Faustmann will present the KHAN/w4i/LDC initiative. This collaborative drug discovery platform facilitates the translation of world-class science into innovative therapies for the benefit of patients. Their mission is to create value through cooperative drug development partnerships with academic innovators in Europe. They focus on first-in-class therapies for attractive markets with a high unmet medical need.
This webinar is organised by the BioMedical SIG and supported by UCB. Join the BioMedical SIG to stay informed.
Technology transfer is ever changing and a key piece for the competitiveness of your institution, this course is an excellent tool to prepare yourself for that challenge.
Ricardo Castro
Centre for research in agricultural Genomics, Spain
A must-do for any staff involved in technology transfer and start-up creation.
Frederic Ratel
Institute of Chemical Research of Catalonia, Spain
Exciting training, even after almost 10 hours I am curious about more experience and knowledge.
Petr Suchomel
Palacký University Olomouc, Czech Republic
ASTP Annual conference is a unique opportunity to take time to exchange best practices among TT professionals and to network at an EU level.
Cécile Cavalade
ULB TTO, Belgium
The expert-panel discussion educated me in strategic and meritorious choice of inventions to approach investors and manage investment funds for establishing a spin off.
Ram Siddappa
Erasmus MC, Netherlands
Join our newsletter and get the latest news